HCP
TWST icon

Hexagon Capital Partners’s Twist Bioscience TWST Stock Holding History

Hexagon Capital Partners’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16
Closed -$628 – 1598
2025
Q1 		$628 Hold
16
– – ﹤0.01% 1617
2024
Q4 		$744 Buy
16
+7
+78% +$316 ﹤0.01% 1643
2024
Q3 		$407 Buy
+9
New +$428 ﹤0.01% 1437

Other funds holding TWST

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Hexagon Capital Partners's TWST Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Twist Bioscience (TWST) in Q2 2025, closing a stake of 16 shares — an estimated $628 sold.

Hexagon Capital Partners first reported a position in TWST in Q3 2024 and held it in 3 quarters. The position peaked at $744 in Q4 2024. 243 funds tracked by Wall St. Rank hold TWST as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Twist Bioscience position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 16 Twist Bioscience shares in Q2 2025, an estimated $628.
  • Hexagon Capital Partners first reported a position in Twist Bioscience in Q3 2024 and held it in 3 quarters.
  • Hexagon Capital Partners's Twist Bioscience position peaked at $744 in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.